Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aker BioMarine AS (AKBM.OL)
Lysaker, NO
Aker BioMarine AS, a subsidiary of Aker ASA, is a Norwegian company established in 2006 and headquartered in Lysaker. The firm is dedicated to the global development, production, and commercialization of ingredients sourced from krill, serving diverse applications in nutraceuticals, dietary supplements, and animal feed. Its market reach extends across Norway, the Americas, Asia Pacific, Europe, the Middle East, and Africa. The company operates through two distinct segments: Ingredients and Brands. Its product portfolio features Superba, a krill-derived nutraceutical ingredient recognized for its phospholipid complex containing choline, omega-3s, and astaxanthin. Other key offerings include QRILL Aqua, designed for aquaculture, and QRILL Pet, tailored for animal feed. Aker BioMarine also provides LYSOVETA, an innovative delivery platform based on LPC-bound EPA and DHA from krill, alongside INVI, a hydrolyzed protein isolate suitable for food and beverage applications. Beyond its core ingredient business, the company distributes natural supplements and various human health and nutrition products. Furthermore, it oversees AION, a circular solutions provider focused on waste recycling and material reuse.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.78% | -0.59% | -5.74% | +3.88% | +21.48% | +4.73% | +77.04% | +171.47% | +29.85% | -2.77% | -2.77% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Packaged Foods: +4.4%+12.8% ★ Q1'26: +12.4% (vs Q1'25)
-
EPS growth Packaged Foods: +14.6%-68.8% Q1'26: -34.6% (vs Q1'25)
-
FCF margin FCF growth · Packaged Foods: +15.9%+5.0% ★ Q1'26: -23.6% (vs Q1'25)
-
EBIT margin Packaged Foods: +7.9%+9.4% ★ Q1'26: +11.7% (vs Q1'25)
-
ROIC Packaged Foods: +7.0%+6.8% Q1'26: +8.4% (vs Q1'25)
-
Share dilution Packaged Foods: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Packaged Foods: 0.19×4.60× Q1'26: 4.49× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
288.59M
est: 287.99M (+0.2%)
|
262.06M
est: 262.41M (-0.1%)
|
277.20M
est: 287.88M (-3.7%)
|
335.30M
est: 31.80M (+954.3%)
|
199.00M
est: 262.04M (-24.1%)
|
224.51M
est: 220.33M (+1.9%)
|
227.24M
219.29M – 235.20M
+3.1% YoY
|
251.22M
239.32M – 263.11M
+10.5% YoY
|
268.76M
257.58M – 279.95M
+7.0% YoY
|
290.13M
278.06M – 302.20M
+7.9% YoY
|
314.83M
301.73M – 327.93M
+8.5% YoY
|
| EBITDA |
67.67M
est: 62.69M (+7.9%)
|
59.30M
est: 57.12M (+3.8%)
|
81.90M
est: 62.66M (+30.7%)
|
49.70M
est: 6.55M (+658.3%)
|
36.60M
est: 54.00M (-32.2%)
|
39.63M
est: 45.41M (-12.7%)
|
46.83M
45.19M – 48.47M
+3.1% YoY
|
51.77M
49.32M – 54.22M
+10.5% YoY
|
55.39M
53.08M – 57.69M
+7.0% YoY
|
59.79M
57.30M – 62.28M
+7.9% YoY
|
64.88M
62.18M – 67.58M
+8.5% YoY
|
| EBIT |
19.43M
est: 10.39M (+86.9%)
|
6.30M
est: 9.47M (-33.5%)
|
32.50M
est: 10.39M (+212.8%)
|
-500.0K
est: 1.32M (-137.9%)
|
-5.30M
est: 10.86M (-148.8%)
|
21.10M
est: 9.13M (+131.2%)
|
9.41M
9.09M – 9.74M
+3.1% YoY
|
10.41M
9.92M – 10.90M
+10.5% YoY
|
11.14M
10.67M – 11.60M
+7.0% YoY
|
12.02M
11.52M – 12.52M
+7.9% YoY
|
13.04M
12.50M – 13.59M
+8.5% YoY
|
| Net Income |
-5.46M
est: -3.16M (-72.7%)
|
-8.01M
est: -7.44M (-7.7%)
|
10.00M
est: 4.13M (+141.9%)
|
-9.00M
est: -1.03M (-770.6%)
|
180.30M
est: 5.25M (+3,331.3%)
|
-23.47M
est: -3.22M (-629.8%)
|
12.27M
10.48M – 14.06M
+481.5% YoY
|
30.67M
24.95M – 36.39M
+150.0% YoY
|
43.22M
40.88M – 45.56M
+40.9% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
82.94M
est: 84.73M (-2.1%)
|
82.75M
est: 77.20M (+7.2%)
|
82.50M
est: 84.70M (-2.6%)
|
90.10M
est: 9.26M (+873.2%)
|
60.00M
est: 76.28M (-21.3%)
|
61.04M
est: 64.14M (-4.8%)
|
66.15M
63.84M – 68.47M
+3.1% YoY
|
73.13M
69.67M – 76.59M
+10.5% YoY
|
78.24M
74.98M – 81.49M
+7.0% YoY
|
84.46M
80.94M – 87.97M
+7.9% YoY
|
91.65M
87.83M – 95.46M
+8.5% YoY
|
| EPS |
-0.07
est: -0.04 (-94.0%)
|
-0.09
est: -0.08 (-7.7%)
|
0.11
est: 0.05 (+133.3%)
|
-1.32
est: -0.01 (-11,359.1%)
|
-0.16
est: 0.06 (-367.1%)
|
-0.27
est: -0.04 (-636.4%)
|
0.14
0.12 – 0.16
+481.5% YoY
|
0.35
0.28 – 0.41
+150.0% YoY
|
0.49
0.47 – 0.52
+40.9% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - International Small Cap ETF DFIS | 0.01% | 355.0K | 0.39% |
| 2 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 140.9K | 0.28% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 115.1K | 0.22% |
| 4 | Dimensional - International Vector Equity ETF DXIV | 0.00% | 206.25 | 0.53% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Matts Johansen | Chief Executive Officer | 9M | male |
| Seth French | Chief Executive Officer of Lang Pharma Nutrition Inc | 5M | male |
| Simon Seward | Chief Executive Officer of Human Health Ingredients | 5M | male |
| Katrine Mourud Klaveness | Chief Financial Officer | 5M | female |
| Trond Atle Smedsrud | Chief Executive Officer of Emerging Business | 3M | male |
| Marte Dalsegg | Executive Vice President of People & Communications | 2M | female |
| Anniken Færgestad | Vice President of Finance | — | — |
| Lise Wiger | Financial Controller | — | female |
| Christopher Robin Vinter | Vice President of IR & Corporate Finance | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AKBM.OL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
